Browse our latest Cancer Biology articles

SIAH2 and OTUD5 orchestrate DBC1 ubiquitination and degradation under hypoxic conditions.

Non-negative Matrix Factorization is a powerful strategy for unsupervised analysis of cell-free DNA that enables simultaneous estimation of the blood tumor fraction and the fragment length distribution of circulating tumor DNA.

Examination of the changes in the transcription start site selection in TCL1-driven chronic lymphocytic leukemia and their impact on mRNA translation revealed a marked elevation of intra-genic cryptic promoters, which are predicted to generate multiple N-terminally truncated or modified proteins.

A novel approach together with a user-friendly web-based analytic tool, coined 'REAP', was proposed to improve the quantitative assessment of dose-response relationship and drug potency.

Bariatric surgery reversed obesity-exacerbated tumor burden and increased efficacy of anti-PD-L1 immunotherapy.

Inhibition of GOT2 drives growth inhibitory reductive stress that can be rescued by electron acceptors in vitro, whereas GOT2 inhibition in endogenous or transplanted tumor models is tolerated without consequence, highlighting the importance of context when studying tumor metabolism.

In response to proteotoxic stress, squamous cell carcinoma cells hijack the integrated stress response to promote recovery by bolstering protection of microtubule dynamics.

Comprehensive proteomic investigation and functional studies unravel an essential role of differentiated glioma cell-secreted fibromodulin (FMOD) in regulating glioblastoma tumor growth by inducing angiogenesis by activating integrin-dependent Notch signaling in endothelial cells, highlighting FMOD as a potential therapeutic target.

Genome-wide CRISPR screens in human cells identifies a role for TRIM37 in growth arrest after chemical inhibition of PLK4.

Cystathionine-β-synthase is a novel metabolic regulator of AKT-induced senescence and a potential tumor suppressor in gastric cancer pathogenesis which can be harnessed to target PI3K/AKT-driven cancers.